-
Scandic Trust Group strengthens sales network with First Idea Consultant
-
Brazil court reaches majority to reject Bolsonaro appeal against jail term
-
Norris grabs pole for Brazilian Grand Prix sprint race
-
More than 1,200 flights cut across US in govt paralysis
-
NFL Cowboys mourn death of defensive end Kneeland at 24
-
At COP30, nations target the jet set with luxury flight tax
-
Trump hosts Hungary's Orban, eyes Russian oil sanctions carve-out
-
All Blacks 'on edge' to preserve unbeaten Scotland run, says Savea
-
Alpine say Colapinto contract about talent not money
-
Return of centuries-old manuscripts key to France-Mexico talks
-
Byrne adamant Fiji no longer overawed by England
-
Ex-footballer Barton guilty over 'grossly offensive' X posts
-
Key nominees for the 2026 Grammy Awards
-
Brazil court mulls Bolsonaro appeal against jail term
-
Rybakina sinks Pegula to reach WTA Finals title match
-
Earth 'can no longer sustain' intensive fossil fuel use, Lula tells COP30
-
Kendrick Lamar leads Grammy noms with nine
-
Ex-British soldier fights extradition over Kenyan woman's murder
-
Kolisi to hit Test century with his children watching
-
Alex Marquez fastest in practice ahead of Portuguese MotoGP
-
Will 'war profiteer' Norway come to Ukraine's financial rescue?
-
Tech selloff drags stocks down on AI bubble fears
-
Blasts at Indonesia school mosque injure more than 50
-
Contepomi says lead-in to Wales match a 'challenge' for Argentina
-
Greece woos US energy deals, as eco groups cry foul
-
Frank says Spurs supporting Udogie through 'terrible situation'
-
MSF warns of missing civilians in Sudan's El-Fasher
-
Norris on top as McLaren dominate opening Sao Paulo practice
-
UN warns 'intensified hostilities' ahead in Sudan despite RSF backing truce plan
-
Seven hospitalized after suspicious package opened at US base
-
Guardiola says 'numbers are insane' as he reaches 1,000 games in charge
-
Brazil welcomes China lift of ban on poultry imports
-
Scotland captain Tuipulotu bids for landmark win over All Blacks
-
Woman convicted in UK of harassing Maddie McCann's parents
-
Tanzania charges more than 100 with treason over election protests
-
Nexperia chip exports resuming: German auto supplier
-
Genge warns England to beware 'nasty' Fiji at Twickenham
-
Stocks fall on renewed AI bubble fears
-
UK grandmother on Indonesia death row arrives back in London
-
Spanish star Rosalia reaches for divine in new album
-
Portugal's Mendes out injured as Neves returns for World Cup qualifiers
-
Afghan-Pakistan peace talks push ahead after border clashes
-
Fleetwood in tie for lead at halfway stage in Abu Dhabi
-
Brazil court starts hearing Bolsonaro appeal
-
Serbia fast-tracks army HQ demolition for Trump family hotel
-
Ireland captain Doris 'mentally stronger' after long break
-
MSF accuses powerful nations of weakening S.Africa's G20 health text
-
Maresca defends Chelsea rotation policy after Rooney criticism
-
Hundreds of flights cut across US in government paralysis
-
Xhaka 'made me a better coach', says Arsenal boss Arteta
Bayer sets aside more cash to deal with weedkiller woes
German pharmaceutical and agricultural chemicals giant Bayer said it had put aside an extra 1.2 billion euros ($1.4 billion) to deal with long-running US legal woes linked to a weedkiller.
It takes to 1.7 billion euros the amount set aside to deal with litigation linked to the glyphosate-based Roundup weedkiller, the German group said in a statement late Thursday.
Bayer also said it had achieved a "major settlement" with a law firm "reducing the total number of unresolved glyphosate claims to 61,000".
This means that a total of 131,000 claims had so far either been settled or deemed not eligible, it said.
The flood of legal cases in the United States relates to claims that the weedkiller causes blood cancer. Bayer says scientific studies and regulatory approvals show that the weedkiller is safe.
The Leverkusen-based group has already spent over $10 billion to settle cases.
Despite the extra provision for the legal cases, Bayer hiked its forecasts for 2025 due to a better-than-expected performance in its pharmaceuticals division.
The maker of Aspirin now expects sales of 46 to 48 billion euros this year up from a previous forecast of 45 to 47 billion.
It also predicted earnings before interest, taxes, depreciation and amortisation -- a key measure of profitability -- of 9.7 to 10.2 billion euros up from a previous forecast of 9.5 to 10 billion.
Its shares were up two percent on the blue-chip DAX index in Frankfurt Friday, while the broader index slipped 1.8 percent.
B.AbuZeid--SF-PST